Bausch Health Companies Inc
BHC
Company Profile
Business description
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Contact
2150 St Elzear Boulvard West
LavalQCH7L 4A8
CANT: +1 514 744-6792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
20,300
Stocks News & Analysis
stocks
AI isn’t an economic moat killer, but it will disrupt industries
How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,571.30 | 125.30 | -1.44% |
| CAC 40 | 7,771.05 | 44.85 | 0.58% |
| DAX 40 | 22,720.31 | 66.45 | 0.29% |
| Dow JONES (US) | 46,208.47 | 631.00 | 1.38% |
| FTSE 100 | 9,929.06 | 34.91 | 0.35% |
| HKSE | 25,062.28 | 679.81 | 2.79% |
| NASDAQ | 21,946.76 | 299.15 | 1.38% |
| Nikkei 225 | 52,252.28 | 736.79 | 1.43% |
| NZX 50 Index | 12,701.75 | 197.97 | -1.53% |
| S&P 500 | 6,581.00 | 74.52 | 1.15% |
| S&P/ASX 200 | 8,379.40 | 125.20 | -1.47% |
| SSE Composite Index | 3,881.28 | 68.00 | 1.78% |